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One sentence summary: Eight RhCMV gene products control induction of unconventionally restricted 
CD8+ T cells and RhCMV/SIV vaccine efficacy 
 
Abstract: Simian immunodeficiency virus (SIV) insert-expressing, 68-1 Rhesus Cytomegalovirus 
(RhCMV/SIV) vectors elicit major histocompatibility complex (MHC)-E- and -II-restricted, SIV-
specific CD8+ T cell responses, but the basis of these unconventional responses and their contribution to 
demonstrated vaccine efficacy against SIV challenge in the rhesus monkeys (RMs) has not been 
characterized. We show that these unconventional responses resulted from a chance genetic 
rearrangement in 68-1 RhCMV that abrogated the function of eight distinct immunomodulatory gene 
products encoded in two RhCMV genomic regions (Rh157.5/Rh157.4 and Rh158-161), revealing three 
patterns of unconventional response inhibition. Differential repair of these genes with either RhCMV-
derived or orthologous human CMV (HCMV)-derived sequences (UL128/UL130; UL146/UL147) leads 
to either of two distinct CD8+ T cell response types – MHC-Ia-restricted-only, or a mix of MHC-II- and 
MHC-Ia-restricted CD8+ T cells. Response magnitude and functional differentiation is similar to 
RhCMV 68-1, but neither alternative response type mediated protection against SIV challenge. These 
findings implicate MHC-E-restricted CD8+ T cell responses as mediators of anti-SIV efficacy and 
indicate that translation of RhCMV/SIV vector efficacy to humans will likely require deletion of all 
genes that inhibit these responses from the HCMV/HIV vector. 
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INTRODUCTION 
CMVs differ from other known viruses in their ability to elicit and indefinitely maintain high frequency 
CD4+ and CD8+ T cell responses with broad tissue distribution and dominant effector-memory 
differentiation (1-3). CMV-based vaccine vectors were developed to exploit this immunobiology, 
addressing the hypothesis that such circulating and tissue-based, effector-differentiated memory T cell 
responses, directed at heterologous pathogens via vaccination, would provide for a rapid immune 
effector intercept of nascent infections, prior to effective pathogen immune evasion (4, 5). This concept 
has been tested in the SIV-RM model of AIDS, where, across multiple studies, 50-60% of rhesus 
macaques (RMs) vaccinated with strain 68-1 RhCMV/SIV vectors show early stringent control with 
replication arrest of highly pathogenic SIVmac239, with the vast majority of protected RMs going on to 
eventually clear the infection (6-8). This “control and clear” pattern of anti-SIV efficacy, which has not 
been documented with any other vaccine modality, is consistent with our hypothesis that an early 
intercept of SIV infection by effector-differentiated memory CD8+ T cells might mediate superior viral 
control. However, unexpectedly, we found that, in contrast to natural RhCMV infection, the epitopes 
targeted by strain 68-1 RhCMV vector-elicited CD8+ T cells are restricted by major histocompatibility 
complex (MHC)-II or MHC-E molecules, and not classical polymorphic MHC-Ia, and include universal 
epitopes (“supertopes”) of both restriction types (9, 10). This unusual finding suggests that an early 
pathogen interception by pre-established effector-differentiated memory CD8+ T cells may not be the 
only mechanism underlying the efficacy of these vectors, but that unconventional CD8+ T cell epitope 
targeting might play a key additional role.  
The 68-1 RhCMV strain was extensively passaged on fibroblasts prior to cloning of the viral genome as 
a bacterial artificial chromosome for vector construction, and during this passage developed genetic 
mutations similar to fibroblast-adapted HCMV strains, resulting in inactivation of the pentameric 
complex, a CMV entry receptor for non-fibroblast cell types that is selected against during fibroblast 
passage (11, 12). In the case of 68-1 RhCMV, pentameric complex inactivation occurred via deletion of 
the genes Rh157.5 and Rh157.4, RhCMV orthologs of HCMV UL128 and UL130, due to a deletion in 
the flanking region of an inverted genome segment (11). Repair of Rh157.5 and Rh157.4 gene expression 
in clone 68-1.2 of RhCMV (13) restored conventional MHC-Ia-restricted-only CD8+ T cell recognition 
(10), suggesting a role of the pentameric complex in this unique reprogramming of vector 
immunogenicity. The pentameric complex facilitates CMV entry into endothelial, epithelial, and 
myeloid-derived cells such as macrophages and dendritic cells which are critical for T cell priming. 
Inactivation of the pentameric complex reduces infection of these cell types (12), thus it is reasonable to 
hypothesize that such modulation of viral tropism affects CD8+ T cell priming by altering direct antigen 
presentation by infected cells. 
Here we sought to characterize the genetic and mechanistic basis of 68-1 RhCMV’s unconventional 
CD8+ T cell response programing, in particular the role of the pentameric complex, and determine 
whether unconventional MHC restriction is necessary for vaccine efficacy, with the ultimate goal of 
defining the vector genotype necessary for clinical development of an efficacy-optimized HCMV-
vectored HIV vaccine. Surprisingly, our analyses revealed that tropism modulation by pentameric 
complex abrogation played only a partial role in programming the MHC restriction of vector-elicited 
CD8+ T cells, with the major regulation mediated by non-pentameric complex-related functions of two 
pentameric complex components and 6 other viral gene products with chemokine homology that were 
also affected by the tissue culture-acquired 68-1 genomic rearrangement. When starting from a wildtype 
RhCMV genome, abrogation of all 8 genes was necessary for vector induction of MHC-E-restricted 
CD8+ T cells, and RhCMV/SIV vaccine efficacy was only observed when such responses were present. 
Taken together these results strongly link MHC-E-restricted CD8+ T cell response with RhCMV/SIV 
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efficacy and point to the importance of these response programming mechanisms to the translation of 
RhCMV/SIV efficacy to an HCMV/HIV vector design suitable for clinical development.  
RESULTS  
Role of the pentameric complex and vector tropism in response programming 
The inversion/deletion event within the genetic region encoding the pentameric complex that occurred 
during in vitro passage of strain 68-1 RhCMV [corresponding to the ULb’ region of HCMV (11)] 
disrupted 2 sets of genes at either end of the inverted segment: Rh157.5/Rh157.4 and Rh158-161 (Fig. 
1A). Repair of Rh157.5/Rh157.4 expression in strain 68-1.2, leaving the Rh158-161 region unchanged, 
restored pentameric complex function (fig. S1) and reverted CD8+ T cell immunogenicity to 
conventional MHC-Ia-restricted responses (Fig. 1B), implicating the pentameric complex in this 
transition. Moreover, administration of both 68-1 and 68-1.2 RhCMV/SIVgag vectors to RMs resulted 
in a mixed SIVgag-specific, CD8+ T cell restriction phenotype, including both conventionally (MHC-Ia-
) restricted and unconventionally (MHC-E- and MHC-II-) restricted responses (Fig. 1B). This 
observation suggests that response programming of a given RhCMV vector is regulated independently 
and likely locally, consistent, as hypothesized above, with programming resulting from differences in 
vector tropism and direct antigen presentation. However, other mechanisms can apply locally, and it is 
possible that the response programming effect of Rh157.5/Rh157.4 deletion was mediated by non-
pentameric complex-related functions of Rh157.5/Rh157.4 gene products or by modulation of non-
Rh157.5/Rh157.4 gene expression.  
To address this issue, we constructed and tested a series of pentameric complex-modified 68-1.2 
RhCMV/gag vectors, asking whether these modifications resulted in changes in the epitope targeting of 
vaccine-induced SIVgag-specific CD8+ T cell responses (Fig. 2A). First, we demonstrated that 
incorporation of stop mutations into the Rh157.5 and Rh157.4 genes converted CD8+ T cell responses 
from targeting MHC-Ia-restricted epitopes (wildtype and 68-1.2 immunotype) to MHC-II- and MHC-E-
restricted epitopes (68-1 immunotype), which demonstrates that protein expression, not alteration of 
genomic configuration by the strain 68-1 inversion-deletion, is responsible for response programming 
(Fig. 2B). We then tested 68-1.2 vectors with genetic modifications that abrogate pentameric complex 
function without complete abrogation of both Rh157.5 or Rh157.4 expression, including deletion (D) of 
Rh157.5 alone, Rh157.4 alone, and functional inactivation of the pentameric complex by alanine-
substitution mutation of two charged cluster (CC) regions of the UL128 ortholog Rh157.5 (14) (fig. S1). 
Surprisingly, the CD8+ T cell responses elicited by these 3 vectors did not recapitulate either the 68-1 or 
68-1.2 CD8+ T cell response types, but instead resulted in a different response type characterized by 
mixed CD8+ T cell targeting of both MHC-Ia- and MHC-II-restricted epitopes, the latter notably without 
supertopes (Fig. 2B).  
To determine whether this new response type was due to alteration of vector tropism, we engineered a 
pentameric complex-independent tropism restriction into the 68-1.2 vector by incorporating target sites 
for the myeloid-specific microRNA (miR)-142-3p into the 3’ untranslated region (UTR) of the viral 
Rh108 and Rh156 genes (orthologs to HCMV UL79 and UL122, respectively) to exploit miR-mediated 
gene expression suppression to change vector tropism (15, 16). By suppressing expression of these 
essential viral genes, this miR target site insertion impedes the vector’s ability to productively infect 
miR-142-3p-expressing myeloid cells, thus simulating one possible effect of pentameric complex 
inactivation relevant to CD8+ T cell response priming – decreased infection efficiency of myeloid-
derived antigen presenting cells (Figs. 3A-C). Notably, this miR-142-3p-restricted 68-1.2 vector elicited 
a very similar pattern of CD8+ T cell epitope targeting (MHC-Ia- + MHC-II-restriction, without 
supertopes) as the DRh157.5, DRh157.4, and CC1+CC2 mutant-Rh157.5 68-1.2 vectors (Figs. 3D), 
except that the MHC-II-restricted CD8+ T cell priming of the former vector was more efficient (88% of 
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total epitopes) than the latter vectors (57% of total epitopes; p<0.001 by binomial exact test). Taken 
together, these data indicate that pentameric complex inactivation alone is not responsible for the full 
development of the exclusively unconventionally targeted CD8+ T cell responses manifested by 68-1 
vectors, but does provide for elicitation of non-supertope, MHC-II-restricted CD8+ T cells, an effect that 
is likely attributable to reduced infection of myeloid-derived cells driven by pentameric complex 
inactivation. Additionally, these data indicate that both the Rh157.5 and Rh157.4 gene products have a 
pentameric complex-independent activity that interferes with elicitation of CD8+ T cell responses to all 
MHC-E-restricted epitopes and to MHC-II-restricted supertopes, potentially related to their N-terminal 
homology with host chemokines (fig. S2).  
Identification of non-pentameric complex-related modulators of response programming 
We next asked the question of whether abrogating both the pentameric complex- and non-pentameric 
complex-related immune programming activities of Rh157.5 and Rh157.4 was sufficient to convert a 
primary isolate-like RhCMV, with conventional MHC-Ia-restricted CD8+ T cell targeting, to a 68-1-like 
vector with exclusively MHC-II- and MHC-E-restricted CD8+ T cell responses. Using sequence 
information from primary RhCMV isolates, including the original 68-1 isolate (17), we reconstructed 
and produced a full length RhCMV clone (RhCMV FL) in which all suspected deletions, inversions, 
frameshifts and premature termination codons affecting viral open reading frames were repaired and the 
Rh13.1 open reading frame (ORF) was replaced by an SIVgag insert (Fig. 4A) (18). RhCMV FL has 
robust in vivo spread (18), and as expected for an essentially wildtype genetic configuration (9), elicits 
MHC-Ia-restricted, CD8+ T cell responses (Fig. 4B). To determine whether inactivation of Rh157.5 and 
Rh157.4 was sufficient for unconventional CD8+ T cell response programming, we deleted both genes 
from RhCMV FL. Unexpectedly, the resulting recombinant vector (RhCMV FL DRh157.5/Rh157.4) 
elicited CD8+ T cell responses showing the same conventional MHC-Ia-restriction as the parent RhCMV 
FL vector (Fig, 4B), suggesting that genes outside the Rh157 region additionally interfere with the 
induction of unconventionally restricted CD8+ T cell responses. Since the inversion/deletion event in 
strain 68-1 RhCMV also affected the viral CXC chemokine-like proteins with similarity to CXCL-1 
encoded by the Rh158-161 genes, which are orthologous to HCMV UL146 and UL147 (11) (Fig. 1A; 
fig. S2), we constructed RhCMV FL vectors with deletions of Rh158-Rh161, either alone or together 
with deletion of Rh157.5 and Rh157.4 (Fig. 4A). Deletion of the Rh158-Rh161 region alone (RhCMV 
FL DRh158-161) also did not change the MHC-Ia restriction of RhCMV FL elicited CD8+ T cell 
responses; however, deletion of both Rh157.5/Rh157.4 and Rh158-Rh161 [double-deleted (dd)  RhCMV 
FL] did result in the same MHC-II- + MHC-E-restricted CD8+ T cell targeting (with supertopes) as the 
original 68-1 RhCMV vector (Fig. 4B), demonstrating that deletion of both these distinct regions from 
a typical circulating RhCMV strain is required for unconventional response programming.  
To determine the effect of each of the eight genes missing from dd RhCMV FL (Rh157.5, Rh157.4, 
Rh158, Rh158.1, Rh158.2, Rh158.3, Rh161.1, Rh161) on CD8+ T cell response programming, we 
engineered their individual expression in the Rh161 locus of the dd RhCMV FL vector (fig. S3). We 
also evaluated adding back dual expression of the pentameric complex components Rh157.5 and 
Rh157.4 to this vector. Adding back expression of Rh157.5 alone or Rh157.4 alone to dd RhCMV FL 
resulted in CD8+ T cell targeting of both MHC-Ia + MHC-II-restricted epitopes, whereas adding 
expression of both resulted in MHC-Ia-only epitope targeting (Fig. 5A), independently confirming the 
findings reported above using the 68-1.2, 68-1.2 DRh157.5, and 68-1.2 DRh157.4 RhCMV vectors. In 
contrast, adding back expression of each of the six Rh158-161 genes individually to dd RhCMV FL 
resulted in reversion to the MHC-Ia-only epitope targeting pattern (Fig. 5B). Although only three of 
these genes are completely deleted in 68-1 RhCMV (Fig. 1A), qPCR analysis indicates that the 
remaining three transcripts are expressed at substantially lower levels in 68-1 compared to RhCMV FL, 
presumably as a consequence of the inversion event resulting in altered transcriptional regulation or ORF 
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truncation (fig. S4). Taken together, these data indicate that wildtype RhCMV encodes highly redundant 
mechanisms to prevent elicitation of unconventionally restricted CD8+ T cell responses, particularly 
MHC-E-restricted CD8+ T cells. These include eight chemokine-related gene products (fig. S2), six of 
which (Rh158-161) inhibit both MHC-E and MHC-II-restricted CD8+ T cell priming, and two of which 
(Rh157.5 and Rh157.4) individually inhibit MHC-E- and MHC-II supertope CD8+ T cell priming and 
that when expressed together with Rh157.6, Rh104/gH, and Rh147/gL (orthologs of HCMV UL131A, 
UL75 and UL115, respectively) create the pentameric complex which additionally inhibits MHC-II non-
supertope CD8+ T cell priming by tropism modulation.  
Conservation of response programming function by HCMV orthologs 
Since our ultimate aim is to develop an HCMV-based vaccine for human use (19), we next asked whether 
the functions that are inhibitory to unconventional response generation are conserved in the HCMV 
orthologs of these gene products. As described for the RhCMV genes above, we engineered dd RhCMV 
FL vectors to individually express HCMV UL128, UL130, UL146, and UL147. Strikingly, these HCMV 
orthologs, though considerably sequence diverse from their RhCMV counterparts (fig. S2), showed the 
same pattern of inhibition of unconventional CD8+ T cell priming exhibited by the corresponding 
RhCMV gene products (Fig. 5C). Of note, stop mutations abrogated the inhibitory activity of HCMV 
UL146, consistent with a function of the UL146 protein being responsible for the observed inhibitory 
activity (Fig. 5C). This remarkable conservation of function strongly suggests that unconventional CD8+ 
T cell response inhibition is also a priority for HCMV infection in humans, and that deletion of at least 
these 4 genes (UL128, UL130, UL146, UL147) from HCMV would be required to elicit 
unconventionally restricted CD8+ T cells. These observations likely explain the lack of unconventionally 
restricted CD8+ T cell responses in humans vaccinated with a pentameric complex negative, but UL130-
, UL146- and UL147-expressing Towne/Toledo chimeric HCMV (20). 
Immunogenicity of response-programmed RhCMV vectors with different immunotypes 
The ability of 68-1 RhCMV to elicit unconventionally restricted CD8+ T cell responses resulted from a 
complex genetic event that precisely abrogated the activity of 8 genes in two non-contiguous, multi-gene 
regions. These data, however, do not indicate whether unconventional CD8+ T cell response priming, 
though present in the 68-1 RhCMV/SIV vectors with demonstrated efficacy (6-8), is required for, or 
associated with efficacy. To address this question, we initiated a vaccine-challenge study to compare the 
T cell immunogenicity and efficacy of RhCMV/SIV vaccines (vector sets comprised of 3 vectors of the 
same genetic configuration, individually expressing SIVgag, retanef, and 5’-pol) that elicit CD8+ T cell 
responses of the three identified CD8+ T cell targeting response types: 1) MHC-E + MHC-II, with 
supertopes (68-1), 2) MHC-Ia-only (68-1.2), and 3) MHC-Ia + MHC-II, no supertopes (68-1.2 
DRh157.5) (Fig. 6A). To ascertain whether a vaccine regimen eliciting CD8+ T cell responses targeting 
a broad combination of all types of CD8+ T cell epitopes (MHC-Ia- and MHC-E- and MHC-II-restricted, 
including supertopes) was possibly more efficacious than individual vector sets, we also studied an 
additional cohort of RMs that were vaccinated with both the 68-1 and 68-1.2 vector sets.  
Longitudinal analysis of SIV-specific CD4+ and CD8+ T cell responses from these RM cohorts (n = 15 
each) showed that the 68-1.2, 68-1.2 DRh157.5, and 68-1+68-1.2 RhCMV/SIV vaccines manifested 
equivalent or greater SIV insert-specific T cell response magnitudes and similar response longevity 
compared to the 68-1 reference vaccine in both blood and bronchoalveolar lavage fluid (BAL, 
representing an effector site) (Figs. 6B,C; fig. S5). Epitope restriction analysis revealed the expected 
MHC restriction patterns for all four RhCMV/SIV vaccines, including supertope recognition only in the 
RMs vaccinated with 68-1 vectors (Fig. 6D; fig. S6). Importantly, in all vaccine groups, the plateau 
phase SIVgag-specific CD4+ and CD8+ T cells manifested the characteristic effector-memory bias of 
RhCMV vector-elicited T cell responses, as well as broadly similar cytokine profiles, indicating that the 
genetic differences between these vectors did not impact the unique characteristics of RhCMV-induced 
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T cell immunogenicity (Figs. 7A,B). We also compared the magnitude of SIVgag-specific CD4+ and 
CD8+ T cell responses in tissues of RMs vaccinated with 68-1 vs. 68-1.2 RhCMV/gag vectors studied at 
necropsy, revealing comparable responses across lymphoid and non-lymphoid tissues (fig. S7). Taken 
together, these data indicate that these vaccines elicit SIV-specific CD8+ T cells with different epitope 
targeting, but the magnitude, longevity, differentiation and tissue distribution of these CD8+ T cells, and 
of the SIV-specific CD4+ T cells, are broadly similar, allowing assessment of the contribution of 
unconventional response targeting to protective efficacy. 
Efficacy of response-programmed RhCMV vectors with different immunotypes 
Starting ninety-one weeks after first vaccination, all vaccinated RM cohorts, and an unvaccinated RM 
cohort (n = 15), were subjected to repeated, limiting dose, intrarectal SIVmac239 challenge, with take 
of infection monitored by de novo induction of SIVvif-specific T cell responses (SIVvif is not present 
in the vaccine inserts and thus such responses are derived from the SIV infection) and plasma viral load 
(pvl), as previously described (6-8). In this well-characterized challenge model, unvaccinated controls 
and non-protected RMs manifest typical peak and plateau-phase SIVmac239 pvl in concert with 
development of SIVvif-specific T cells, whereas protected RMs show development of SIVvif-specific 
responses in the absence of plasma viremia or with non-sustained pvl blips, and manifest cell-associated 
SIV DNA and/or RNA in tissues consistent with replication arrest (6-8). As expected, all unvaccinated 
RMs showed typical progressive infection, whereas 8 of 15 (53%) of the 68-1 vector vaccinated RMs 
showed protection (Figs. 8A,B). However, none of the RMs vaccinated with the 68-1.2 vectors or 68-
1.2 DRh157.5 vectors manifested protection, but notably, protection was still observed in 6 of the 15 
(40%) RMs vaccinated with both 68-1 and 68-1.2 vectors (p = not significant relative to 68-1) (Figs. 8C-
E). Protected RMs in both the 68-1 and 68-1 + 68-1.2 RhCMV/SIV vector vaccinated groups manifested 
cell-associated SIV DNA and/or RNA in bone marrow (BM) and lymph node (LN), confirming take of 
infection, and given the absence of measurable viremia, replication arrest (Fig. 8F). Thus, although the 
RhCMV vectors programmed for the alternative CD8+ T cell targeting response types (MHC-Ia- + MHC-
II-restricted) elicited CD8+ T cell responses with similar magnitude and qualitative characteristics as 68-
1 vectors, these responses were unable to provide protection against SIV challenge. 
Discussion 
These data demonstrate that the deletion of 8 genes – Rh157.5/Rh157.4 and Rh158-161 – from an intact, 
circulating isolate-like RhCMV genetic configuration is both necessary and sufficient for converting 
RhCMV vector-elicited CD8+ T cell responses from targeting conventional, MHC-Ia-restricted epitopes 
to targeting unconventional, MHC-E- or MHC-II-restricted epitopes, with deletion or functional 
inactivation of these 8 genes by a chance genetic rearrangement accounting for the unconventional CD8+ 
T cell priming originally observed in RMs vaccinated with 68-1 RhCMV vectors (9, 10). Three activity 
patterns were identified, including pentameric complex (tropism)-dependent and -independent inhibition 
of MHC-E and MHC-II supertope priming by Rh157.5/Rh157.4, and pan-unconventional response 
inhibition by Rh158-161. It is notable that these activities are all inhibitory, in particular having in 
common inhibition of MHC-E-restricted CD8+ T cell priming. Given that conventional MHC-Ia-
restricted CD8+ T cells are the default response in wildtype RhCMV and essentially all other virus-
induced CD8+ T cell responses, these data raise the question of why RhCMV encodes multiple redundant 
inhibitors of what can only be considered an unnatural response. 
In this regard, CMV is the epitome of sophisticated host modulation and immune evasion by a virus (21), 
and it is likely that the answer to this question lies in this host modulation/immune evasion biology. 
Indeed, in a companion manuscript (22), we demonstrate that 68-1 RhCMV vectors deleted for Rh67, 
the gene product which is responsible for intracellular transport of MHC-E in RhCMV-infected cells 
(UL40 in HCMV), specifically fail to prime MHC-E-restricted CD8+ T cells, leaving CD8+ T cell 
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responses which are entirely MHC-II-restricted. Thus, MHC-E-restricted CD8+ T cell responses appear 
to be one consequence of intracellular transport with enhanced surface expression of MHC-E mediated 
by the Rh67 gene product. Since MHC-E expression on the surface of infected cells sends a dominant 
inhibitory signal through NKG2A receptors of NK cells, thereby down-modulating NK cell anti-viral 
activity, maintaining high MHC-E expression on the infected cell surface is thought to be an important 
CMV strategy for NK cell evasion, especially since CMV efficiently down-regulates MHC-Ia, 
increasing susceptibility to NK cell-mediated lysis (21, 23-27). However, this NK cell evasion benefit 
would appear to come at the price of enhanced (MHC-E-mediated) CD8+ T cell recognition of CMV-
infected (MHC-Ehigh) cells, especially since efficient MHC-Ia down-regulation by different CMV 
immune evasins precludes efficient recognition of infected cells by classical CD8+ T cells (22). Thus, 
the 8 gene inhibitory system described here likely reflects CMV adaptation to this deleterious side-effect 
of MHC-E upregulation, allowing the virus to evade NK cells without the hindrance of enhanced CD8+ 
T cell recognition mediated by MHC-E-restricted responses. The basis for MHC-II-restricted CD8+ T 
cell priming by RhCMV vectors remains to be determined but given the potential for such responses to 
mediate CD8+ T cell recognition of infected MHC-II+ cells such as monocyte/macrophages and dendritic 
cells, it may not be surprising that CMV co-evolved mechanisms to prevent priming of these responses 
as well. 
Taken together, these data demonstrate that RhCMV has evolved the ability to control the nature of its 
own recognition by CD8+ T cells. To our knowledge, given the capabilities of this virus, this may the 
only virus-based vaccine vector system at this time that is genetically programmable with respect to 
CD8+ T cell epitope targeting. In the companion manuscript we document that exclusively MHC-II-
restricted SIV-specific CD8+ T cell responses, with MHC-II supertope recognition, elicited by the Rh67-
deleted 68-1 RhCMV/SIV vectors are unable to provide protection against SIV challenge (22). Thus, 
neither MHC-Ia-restricted CD8+ T cell responses, nor MHC-II-restricted CD8+ T cell responses (with or 
without supertopes) are able to mediate protection against SIV challenge, even though these responses 
are of similar magnitude and differentiation than the protective responses elicited by 68-1 RhCMV/SIV 
vectors. CD4+ T cell responses are also comparable across the differentially programmed RhCMV/SIV 
vaccines and antibody responses are largely absent in 68-1 RhCMV/SIV vaccinated RMs (6-8, 28), thus 
the presence of MHC-E-restricted CD8+ T cell responses are the only clear difference in adaptive (SIV-
specific) immunity between efficacious and non-efficacious RhCMV/SIV vectors. Since SIV inserts 
(and thus SIV-specific immunity) are demonstrably required for efficacy (7), these data strongly suggest 
that the MHC-E-restricted CD8+ T cell response is the crucial adaptive immune component of 
RhCMV/SIV vector immunogenicity that mediates “control and clear” protection. The specific immune 
functions mediating this efficacy in vivo remain to be elucidated, especially delineation of why MHC-
E-restricted CD8+ T cell responses are uniquely efficacious. Nonetheless, these data indicate that not 
only is epitope-targeting programmability a characteristic of RhCMV vectors, the ability of this 
programming to produce MHC-E-restricted CD8+ T cell responses appears to be necessary for efficacy 
against SIV. 
One important caveat of these findings is that while RhCMV infection of RMs is biologically analogous 
to HCMV infection of humans (29), these are different infectious agents adapted to different hosts, and 
it therefore remains uncertain whether the biology underlying the efficacy of RhCMV/SIV vectors in 
RMs will translate to humans. However, the finding that the HCMV orthologs of the RhCMV genes that 
mediate CD8+ T cell response programming, including UL128/UL130, UL146/UL147 and UL40 (22), 
recapitulate the response programming function of their RhCMV counterparts when used to replace these 
counterparts in RhCMV suggests the conservation of CD8+ T cell response programming in HCMV. 
Moreover, a recent report has identified MHC-E-restricted, HIV-specific CD8+ T cells in humans and 
demonstrated that these T cells can recognize HIV-infected cells in vitro and suppress HIV infection 
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(30). Thus, the available data support the possibility that a UL128/UL130 + UL146/147-deleted 
HCMV/HIV modeled after the dd RhCMV/SIV vectors described here will elicit functional MHC-E 
restricted, HIV-specific CD8+ T cell responses in humans, an hypothesis that is currently being tested in 
a Phase 1 clinical trial (31). Since MHC-E is ubiquitously expressed, non-polymorphic and often 
upregulated in disease (23, 24, 32), an MHC-E-restricted CD8+ T cell response-inducing HCMV-based 
vaccine vector may also be applicable to other pathogens or malignancies. 
MATERIALS AND METHODS 
Study Design 
This study had two major objectives. First, we sought to determine the molecular genetic basis of 
unconventional CD8+ T cell response programming by strain 68-1 RhCMV vectors, knowing that 
naturally occurring RhCMVs elicit conventional MHC-Ia-restricted CD8+ T cells, whereas the 
genetically distinct 68-1 RhCMV elicits a mixture of MHC-II- and MHC-E-restricted CD8+ T cells (9, 
10). We had previously identified the complex inversion/deletion in the genomic region of RhCMV 
orthologous to the ULb’ region of HCMV as the likely basis of this immune programming (Fig. 1A), but 
the specific contribution of the affected genes was unclear, as well as the spectrum of immunologic 
phenotypes (response types) that might arise from different configurations of this gene region. Once the 
genetic determinants of unconventional CD8+ T cell response priming were identified and the spectrum 
of different response types established, our second major objective was to both compare the overall 
immunogenicity of all distinct RhCMV response types and to determine whether the RhCMV vectors 
eliciting these alternative response types were able to mediate the unique replication arrest form of 
protective efficacy previously described for 68-1 RhCMV/SIV vectors (6-8). We sought to determine 
the basis of 68-1 RhCMV/SIV vector efficacy, in particular the dependence of this efficacy on 
unconventional CD8+ T cell epitope targeting. 
Our approach to Objective #1 was to 1) construct SIVgag-expressing RhCMV vectors with defined 
deletions, additions, or functional inactivations of specific open reading frames (ORFs) in the ULb’ 
ortholog region, 2) strategically vaccinate monkeys with these variants, 3) determine the effect of each 
ORF modification on CD8+ T cell recognition of SIV epitopes (with 34 to >500 epitopes analyzed), and 
4) confirm gene contributions and response types with multiple distinct, but functionally overlapping, 
vectors (table S1). For Objective #2, we selected 3 vector backbones and 1 vector backbone combination 
for comparison, encompassing the 3 response types identified in our genetic modification studies (MHC-
Ia-only, MHC-Ia + MHC-II, MHC-E + MHC-II with supertopes) and a combination phenotype that 
elicited all these responses. Based on previous experience with 68-1 RhCMV/SIV vectors (6-8), we 
randomly assigned male RMs to one of the vaccine groups or to serve as unvaccinated controls (n=15 
per group; n=75 total). This group size was anticipated to allow us to thoroughly compare overall 
immunogenicity of each vector backbone or combination and to detect per-vaccine-group protection 
levels of 14% at 90% power without multiplicity adjustment. All results from these experiments are 
included in the presented associated data (no data were excluded as outliers). Plasma and cell-associated 
viral load assays were performed by blinded analysis; however, due to logistical constraints, other staff 
were not blinded to treatment assignments.  
Rhesus macaques  
These experiments used a total of 124 purpose-bred male and female RMs (M. mulatta) of Indian genetic 
background, including 1) 43 RMs for immunogenicity analysis of gene-modified 68-1, 68-1.2 and FL 
RhCMV/gag vectors, 2) 75 RMs for immunogenicity and efficacy analysis of RhCMV vector backbones 
representing distinct response types (5 groups of n = 15, 4 groups vaccinated; 1 group unvaccinated), 
and 3) 6 RMs for RhCMV 68-1.2 vs. 68-1 vector immunogenicity analysis at necropsy. Of note, the 68-
1 vaccine group from this study serves as a positive control group for the companion manuscript (22). 
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RhCMV vectors were routinely dosed at 106-107 infectious units for immunogenicity analysis and 5x106 
infectious units per vector for efficacy analysis, all via subcutaneous administration. At assignment, all 
study RMs were free of cercopithicine herpesvirus 1, D-type simian retrovirus, simian T-lymphotrophic 
virus type 1, and Mycobacterium tuberculosis, but all except one (RM38 in fig. S7) were naturally 
RhCMV-infected. All study RMs were housed at the Oregon National Primate Research Center 
(ONPRC) in Animal Biosafety level (ABSL)-2 (vaccine phase) and ABSL-2+ rooms (challenge phase) 
rooms with autonomously controlled temperature, humidity, and lighting. Study RMs were both single- 
and pair-cage housed. Animals were only paired with one another during the vaccine phase if they were 
from the same vaccination group. All RMs were single cage-housed during the challenge phase due to 
the infectious nature of the study. Regardless of their pairing, all animals had visual, auditory and 
olfactory contact with other animals. Single cage-housed RMs received an enhanced enrichment plan 
that was designed and overseen by NHP behavior specialists. RMs were fed commercially prepared 
primate chow twice daily and received supplemental fresh fruit or vegetables daily. Fresh, potable water 
was provided via automatic water systems. Physical exams including body weight and complete blood 
counts were performed at all protocol time points. RMs were sedated with ketamine HCl or Telazol for 
procedures, including intradermal and subcutaneous vaccine administration, venipuncture, 
bronchoalveolar lavage, BM and LN biopsy, and SIV challenge. At humane or scheduled endpoints, 
RMs were euthanized with sodium pentobarbital overdose (>50 mg/kg) and exsanguinated via the distal 
aorta, and tissue collection at necropsy was performed by a certified veterinary pathologist.  
RM care and all experimental protocols and procedures were approved by the ONPRC Institutional 
Animal Care and Use Committee (IACUC). The ONPRC is a Category I facility. The Laboratory Animal 
Care and Use Program at the ONPRC is fully accredited by the American Association for Accreditation 
of Laboratory Animal Care (AAALAC) and has an approved Assurance (#A3304-01) for the care and 
use of animals on file with the NIH Office for Protection from Research Risks. The IACUC adheres to 
national guidelines established in the Animal Welfare Act (7 U.S.C. Sections 2131–2159) and the Guide 
for the Care and Use of Laboratory Animals (8th Edition) as mandated by the U.S. Public Health Service 
Policy. 
Generation of recombinant RhCMV vectors  
SIV insert (SIVgag, retanef, 5’pol)-expressing vaccine vectors based on RhCMV 68-1 (GenBank 
#MT157325) have been described previously (6, 33). All other RhCMV constructs used in this study 
were based on either the partially-repaired RhCMV 68-1.2 strain (GenBank #MT157326) or our fully 
reconstructed FL RhCMV clone (GenBank #MT157327) (13, 18). Following the original 68-1 vector 
design, SIV inserts were introduced into the Rh211 open reading frame (ORF) in RhCMV 68-1.2 and 
transgene expression was driven by an EFIα promoter. For FL-RhCMV vectors, this design was altered 
and SIV transgenes were inserted into the Rh13.1 ORF using the endogenous promoter and regulatory 
elements to drive expression. This configuration resulted in increased genome stability as Rh13.1 is 
selected against in low passage isolates during tissue culture (18). To introduce deletions into these 
bacterial artificial chromosomes using recombineering we either chose a classical lambda (λ) Red 
recombination system in combination with flippase recognition target (FRT) sites (34), en passant 
recombination (35) or galactokinase- (galK-) mediated bacterial artificial chromosome recombination 
(36). Red recombination is performed by amplifying an aminoglycoside 3-phosphotransferase gene 
conferring kanamycin resistance (KanR) flanked by FRT sites with primers carrying a 50bp homology 
arm to the upstream and downstream region of the targeted genomic locus. This PCR product is inserted 
into the bacterial artificial chromosome through homologous recombination by heat shock induced 
expression of the lambda prophage encoded red recombination genes. After XmaI restriction digest and 
Sanger sequencing across the altered sequence, the selection marker is removed through the arabinose 
inducible expression of a flip recombinase in the EL250 or SW105 strains of E. coli. Final constructs 
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were analyzed by restriction digest and Sanger sequencing of the altered genomic regions. Unintended 
off-target alterations in the genome sequence were ruled out by next generation sequencing (NGS) of 
the complete genome using an Illumina MiSeq or iSeq sequencing platform.  
The en passant recombination technique utilizes a strategy which includes the introduction of 50bp DNA 
repeats during primer design flanking the KanR selection marker. An I-SceI homing enzyme target 
sequence is introduced between the selection marker and the 5’homology arm, which can be used to 
selectively introduce DNA double strand breaks after arabinose inducible expression of the homing 
enzyme in E. coli strain GS1783. These breaks can be repaired via recombination of the repeated DNA 
sequences flanking the selection marker by inducing the expression of the lambda phage derived Red 
recombination genes through heat shock, resulting in complete removal of the KanR resistance cassette 
without retaining any DNA sequences introduced during recombineering (scarless removal). Hence, the 
latter technique was favored for the introduction of point mutations or the alteration of neighboring 
amino acids so as to not disturb the overall coding region. We also used this technique to introduce 
HCMV TR3 (#MN075802) or RhCMV FL derived ORFs into the Rh161 locus in dd RhCMV FL using 
the endogenous regulatory elements to drive gene expression. As described for the lambda Red 
recombination system, all constructs were analyzed by XmaI restriction digest, Sanger sequencing of the 
altered genome region as well as full genome analysis by NGS before virus reconstitution. 
The RhCMV 68-1.2-miR-142-3p and 68-1.2-scrambled miR control vectors expressing SIVgag were 
constructed using galactokinase- (galK-) mediated bacterial artificial chromosome recombination. The 
SW105 E. coli strain carrying the 68-1.2 SIVgag bacterial artificial chromosome was used to introduce 
an expression cassette encoding the galactokinase as well as the KanR gene flanked by 80bp homology 
arms to the targeted regions in the Rh156 or Rh108 3’ untranslated regions. Correctly recombined clones 
were identified based on the production of bright pink colonies on MacConkey agar containing 
kanamycin and Sanger sequencing of the inserted region. The galK-KanR cassette was replaced by the 
insert of interest by homologous recombination and correctly recombined clones were identified through 
negative selection on 2-deoxy-galactose-containing plates. These constructs were also analyzed by 
restriction digest, Sanger sequencing of the inserted region as well as full genome analysis by NGS 
before virus reconstitution. 
RhCMV vector recovery and characterization  
All vectors derived from bacterial artificial chromosomes were reconstituted in primary embryonal 
rhesus fibroblasts (RFs) via electroporation (250V, 508 950μF) of purified bacterial artificial 
chromosome-DNA. The cells were maintained in DMEM complete, Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum and antibiotics (1× Pen/Strep; Gibco) and grown at 37°C 
in humidified air with 5% CO2. Depending on the reconstituted construct, viral plaques became visible 
within 3-5 days and full cytopathic effect (CPE) was observed within 1-2 weeks after electroporation. 
At this point, cells and supernatants were harvested and stored at -80°C until final use. Viral stocks were 
produced on RFs by infecting eight confluent T-175 tissue culture flasks with an approximate MOI of 
0.05-0.1. After full CPE was reached within 4-8 days cells and supernatants were harvested and frozen 
once overnight at -80°C to release intracellular virus from infected cells. Subsequently the supernatant 
was clarified by centrifugation in two steps, first at 2,000 x g for 10 minutes at 4°C and secondly at 7,500 
x g for 15 minutes, after which the virus was purified through a sorbitol cushion (20% D-sorbitol, 50 
mM Tris [pH 7.4], 1 mM MgCl2) by centrifugation at 64,000 x g for 1 hour at 4°C in a Beckman SW28 
rotor. The pelleted virus was resuspended in complete DMEM, aliquoted and stored at -80°C until use. 
Virus titers of all RhCMV stocks were determined by fifty-percent tissue culture infective dose (TCID50) 
assay on RFs and expression of the utilized SIV immunological marker was confirmed by immunoblot. 
To determine which RhCMV constructs contained a functional pentameric complex, we compared entry 
into rhesus retinal pigment epithelial cells (RPE) to entry into primary rhesus fibroblast (RF). RPEs were 
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a kind gift from Dr. Thomas Shenk (Princeton University, USA) and were propagated in a 1:1 mixture 
of DMEM and Ham’s F12 nutrient mixture with 5% FBS, 1 mM sodium pyruvate, and nonessential 
amino acids. Both RFs and RPEs were infected with a MOI determined on RF resulting in infection 
levels of 20-30 percent after 48 hours of infection (MOI of 0.3 for 1RFs and MOI of 10 for RPEs) using 
the pentameric complex-intact RhCMV strain 68-1.2 as a positive control. Infection levels were 
determined by flow cytometry using a RhCMV specific antibody (37) and infection levels were 
expressed by setting infection in RFs to 100 per cent and expressing infection levels in RPEs in relation 
to infection levels in RFs. RhCMV strains 68-1 and 68-1.2 were included in all assays as negative and 
positive controls, respectively, and all experiments were performed with triplicate repeats.  
To analyze the growth restriction of the RhCMV-miR-142-3p vector, multi-step growth curve assays 
were performed on primary rhesus fibroblasts transiently transfected with miR-142-3p or a negative 
control mimic. 12-well plates seeded with RFs were transfected with 20pmol miRNA mimic/well 
(Dharmacon) using RNAiMax (Invitrogen) according to the manufacturer’s instructions. 24 hours later 
the cells were infected with RhCMV-miR-142-3p or the scrambled control virus at a multiplicity of 
infection of 0.01. Supernatants were collected at the indicated timepoints and titered using a standard 
plaque assay on RFs. To analyze growth restriction in primary rhesus macrophages, rhesus PBMC were 
isolated from whole blood using Ficoll and monocytes were purified using non-human primate CD14+ 
microbeads (Miltenyi). The isolated monocytes were cultured in 50% complete RPMI supplemented 
with 10% FBS, 18ng/mL human GM-CSF (R&D Systems) and 20ng/mL human M-CSF (R&D Systems) 
and 50% conditioned media from the cell line KPB-m15 (2) for 7 days on Primaria plates (ThermoFisher 
Scientific). One half media exchange occurred on days 2, 4 and 6. After this time cells had adhered to 
the Primaria plates and differentiated to a typical macrophage morphology. Macrophages were infected 
with RhCMV 68-1.2 miR-142-3p or scrambled control vector at MOI = 5 and cell lysates was harvested 
at the indicated times post-infection using Trizol (Invitrogen). DNA was isolated and used to perform 
quantitative PCR (qPCR) for RhCMV genomes using custom primers and probe sets (ThermoFisher 
Scientific) for RhCMV Rh156: RhCMV Rh156 F primer: GGGCATCCTCAGGATCACAG; RhCMV 
Rh156 R primer: CGACACCAAGAGGGTATGGG; RhCMV Rh156 probe: 6FAM-
ACTCCGAAGACCACAAGGACCCACG-BHQ1. Standard curves were prepared using RhCMV 
bacterial artificial chromosome DNA. 
Expression analysis of RhCMV encoded inhibitors of unconventionally restricted CD8+ T-cell 
priming  
Primary rhesus fibroblasts were seeded out in tissue culture plates and infected the next day with either 
RhCMV FL, 68-1, or 68-1.2 at a MOI of 5. Mock infected wells were included as negative control 
samples. The cells were harvested at 0, 4, 8, 12, 24, 36, and 48 hours post infection (hpi) and total RNA 
was isolated using the Quick RNA Microprep kit (Zymo Research) according to the manufacturer’s 
instructions. 1 µg of total RNA per sample was transcribed into cDNA using the Maxima Reverse 
Transcriptase (ThermoFischer Scientific). To examine the transcript levels and kinetics of selected 
RhCMV ORFs, a q-PCR assay was applied to the cDNA using TaqMan Fast Advanced Master Mix 
(Applied Biosystem). qPCR reactions were performed using QuantStudio 7 Flex Real-Time PCR 
Systems (Applied Biosystems) and data were collected using the QuantStudio Real-Time PCR Software 
v1.3. All determined transcript copy numbers were normalized to the housekeeping gene (GAPDH) and 
results for each gene and time point are expressed as relative mRNA copy numbers. As controls for our 
kinetic class analysis, we included the known immediate early (IE) gene Rh156 (UL123, IE1), the 
characterized early (E) gene Rh189 (US11) as well as the described true late (L) gene Rh137 (UL99, 
pp28). Each forward and reverse primer set was used initially to generate a PCR fragment specific for 
each gene which was cloned into the pGEM-T Easy Vector (Promega) according to the manufacturer’s 
instructions. These plasmids were used for the generation of primer/probe set specific standard curves 
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for each indicated gene which were required to calculate viral genome copy numbers. The primer/probe 
sets used in this study are listed in table S2. 
Immunologic assays 
SIV-specific CD4+ and CD8+ T cell responses were measured in peripheral blood mononuclear cells 
(PBMC) or tissue-derived mononuclear cells by flow cytometric intracellular cytokine analysis, as 
previously described (6-8). Briefly, individual or whole protein mixes of sequential 15-mer peptides (11 
amino acid overlap) spanning the SIVmac239 Gag, 5’-Pol, Nef, Rev, Tat, and Vif proteins or individual 
SIVmac239 Gag supertope peptides [Gag211-222 (53), Gag276-284 (69), Gag290-301 (73), Gag482-490 (120)] were 
used as antigens in conjunction with co-stimulatory anti-CD28 (CD28.2, Purified 500 ng/test: 
eBioscience, Custom Bulk 7014-0289-M050) and anti-CD49d mAb (9F10, Purified 500 ng/test: 
eBioscience, Custom Bulk 7014-0499-M050). Mononuclear cells were incubated at 37°C with 
individual peptides or peptide mixes and antibodies for 1 hr, followed by an additional 8 hr incubation 
in the presence of Brefeldin A (5 μg ml−1; Sigma-Aldrich). Stimulation in the absence of peptides served 
as background control. After incubation, stimulated cells were stored at 4°C until staining with 
combinations of fluorochrome-conjugated monoclonal antibodies including: anti-CD3 (SP34-2: 
Alexa700; BD Biosciences, Custom Bulk 624040 and Pacific Blue; BD Biosciences, Custom Bulk 
624034), anti-CD4 (L200: AmCyan; BD Biosciences, Custom Bulk 658025, BV510; BD Biosciences, 
Custom Bulk 624340 and BUV395; BD Biosciences, Custom Bulk 624165), anti-CD8a (SK1: PerCP-
eFluor710; Life Tech, Custom Bulk CUST04424), anti-TNF-α (MAB11: FITC; BD Biosciences, 
Custom Bulk 624046 and PE; BD Biosciences, Custom Bulk 624049), anti-IFN-γ (B27: APC; BD 
Biosciences, Custom Bulk 624078) and anti-CD69 (FN50: PE; eBioscience, Custom Bulk CUST01282 
and PE-TexasRed; BD Biosciences, Custom Bulk 624005) and for polycytokine analyses, anti-IL-2 
(MQ1-17H12; PE Cy-7; Biolegend), and anti-MIP-1β (D21-1351, BV421; BD Biosciences). For 
analysis of memory differentiation (central- vs transitional- vs effector-memory) of SIV Gag-specific 
CD4+ and CD8+ T cells, PBMC were stimulated as described above, except that the CD28 co-stimulatory 
mAb was used as a fluorochrome conjugate to allow CD28 expression levels to be later assessed by flow 
cytometry, and in these experiments, cells were surface-stained after incubation for lineage markers 
CD3, CD4, CD8, CD95 and CCR7 (see below for mAb clones) prior to fixation/permeabilization and 
then intracellular staining for response markers (CD69, IFN-γ, TNF-α; note that Brefeldin A treatment 
preserves the pre-stimulation cell-surface expression phenotype of phenotypic markers examined in this 
study). 
Stained samples were analyzed on an LSR-II or FACSymphony A5 flow cytometer (BD Biosciences). 
Data analysis was performed using FlowJo software (Tree Star). In all analyses, gating on the 
lymphocyte population was followed by the separation of the CD3+ T cell subset and progressive gating 
on CD4+ and CD8+ T cell subsets. Antigen-responding cells in both CD4+ and CD8+ T cell populations 
were determined by their intracellular expression of CD69 and either or both of the cytokines IFN-γ and 
TNF-α (or in polycytokine analyses, expression of CD69 and any combination of the cytokines: IFN-γ, 
TNF-α, IL-2, MIP-1β). Assay limit of detection was determined as previously described (28), with 0.05% 
after background subtraction being the minimum threshold used in this study. After background 
subtraction, the raw response frequencies above the assay limit of detection were “memory-corrected” 
(e.g., % responding out of the memory population), as previously described (6-8, 28), using combinations 
of the following fluorochrome-conjugated mAbs to define the memory vs naïve subsets CD3 (SP34-2: 
Alexa700 and PerCP-Cy5.5; BD Biosciences Custom Bulk 624060), CD4 (L200: AmCyan), CD8a (SK-
1: PerCP-eFluor710, RPA-T8: APC; BioLegend), TNF-α (MAB11; FITC), IFN-γ (B27; APC), CD69 
(FN50; PE), CD28 (CD28.2; PE/Dazzle 594, BioLegend), CD95 (DX2; PE, BioLegend), CCR7 (15053; 
Biotin, R&D Systems), streptavidin (Pacific Blue, Life Tech and BV605; BD Biosciences, Custom Bulk 
624342) and Ki67 (B56; FITC, BD Biosciences, Custom Bulk 624046). For memory phenotype analysis 
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of SIV Gag-specific T cells, all CD4+ or CD8+ T cells expressing CD69 plus IFN-γ and/or TNF-α were 
first Boolean OR gated, and then this overall Ag-responding population was subdivided into the memory 
subsets of interest on the basis of surface phenotype (CCR7 vs. CD28). Similarly, for polycytokine 
analysis of SIV Gag-specific T cells, all CD4+ or CD8+ T cells expressing CD69 plus cytokines were 
Boolean OR gated and polyfunctionality was delineated with any combination of the four cytokines 
tested (IFN-γ, TNF-α, IL-2, MIP-1β) using the Boolean AND function. Gating strategies for these ICS 
analyses are illustrated in fig. S8. 
The MHC restriction type (MHC-Ia, MHC-E, MHC-II) of a 15mer peptide response was determined by 
pre-incubating isolated mononuclear cell aliquots for 1 hr at room temperature (prior to adding peptides 
or combining effector and target cells and incubating per the standard ICS assay) in the presence (and 
absence) of each the following specific inhibitors: 1) the pan anti-MHC-I mAb W6/32 (10µg/ml), 2) the 
MHC-II-blocking mAb G46.6 (10µg/ml), or 3) the MHC-E blocking VL9 peptide (VMAPRTLLL; 
20μM). Stimulated cells were fixed, permeabilized, stained and analyzed as described above. To be 
considered MHC-E-restricted by blocking, the individual peptide response must have been blocked by 
both anti-pan MHC-I clone W6/32 and MHC-E-binding peptide VL9, and not blocked by anti-MHC-II. 
MHC-II-restricted responses were blocked by anti-MHC-II but not anti-MHC-I or VL9, and MHC-Ia-
restricted responses were blocked by anti-MHC-Ia only (9, 10). Responses that did not meet these 
inhibition criteria were considered indeterminate. Minimal independent epitope numbers were estimated 
from the positive responses identified by testing of consecutive 15mer peptides by the following criteria: 
single positive peptide of same restriction type = 1 independent epitope; 2 adjacent positive peptides of 
same restriction type = 1 independent epitope; 3 adjacent positive peptides of same restriction type = 2 
independent epitopes; 4 adjacent positive peptides of same restriction type = 2 independent epitopes; 
and 5 adjacent positive peptides of same restriction type = 3 independent epitopes. 
SIV detection assays  
Plasma SIV RNA levels were determined using an SIVgag-targeted quantitative real time/digital RT-
PCR format assay, essentially as previously described, with 6 replicate reactions analyzed per extracted 
sample for assay thresholds of 15 SIV RNA copies/ml (7, 8, 38). Quantitative assessment of SIV DNA 
and RNA in cells and tissues was performed using SIVgag targeted, nested quantitative hybrid real-
time/digital RT-PCR and PCR assays, as previously described (7, 8, 38). SIV RNA or DNA copy 
numbers were normalized based on quantitation of a single copy rhesus genomic DNA sequence from 
the CCR5 locus from the same specimen, as described, to allow normalization of SIV RNA or DNA 
copy numbers per 108 diploid genome cell equivalents. Ten replicate reactions were performed with 
aliquots of extracted DNA or RNA from each sample, with two additional spiked internal control 
reactions performed with each sample to assess potential reaction inhibition. Samples that did not yield 
any positive results across the replicate reactions were reported as a value of “less than” the value that 
would apply for one positive reaction out of 10. Threshold sensitivities for individual specimens varied 
as a function of the number of cells or amount of tissue available and analyzed; for graphing consistency 
values are plotted with a common nominal sensitivity threshold. 
Statistical Analysis  
Boxplots show jittered points and a box from 1st to 3rd quartiles (IQR) and a line at the median, with 
whiskers extending to the farthest data point within 1.5*IQR above and below the box. For all 
comparisons of T cell response parameters, we performed Wilcoxon rank-sum tests comparing each non-
RhCMV 68-1 vaccine group to the RhCMV 68.1 reference group. For longitudinal responses, we 
calculated the area under the curve (AUC) or the plateau average value for each RM, as denoted in the 
figure legends. All Wilcoxon P values are based on two-sided tests and unadjusted except where noted. 
Adjusted P values were computed using the Holm procedure for family-wise error rate control. All P 
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values for analyses of efficacy or epitope restriction frequency were based on two-sided exact tests of 
binomial proportions. Analyses were performed in R v3.6.0 with the package Exact v2.0 (39). 
SUPPLEMENTARY MATERIALS 
Fig. S1. Functional pentameric complex analysis of 68-1.2-based RhCMV vectors 
Fig. S2. Protein sequence comparison of RhCMV/HCMV orthologs RhCMV157.5/UL128, Rh157.4/ 
UL130 and Rh158-161/UL146-147   
Fig. S3. Genetic configuration of gene-modified double-deleted (dd) FL-RhCMV vectors 
Fig. S4. Transcriptional analysis of Rh158-Rh161 region genes in RhCMV FL in comparison to 
RhCMV 68-1 and 68-1.2 
Fig. S5. Analysis of SIV-specific T cell responses in bronchoalveolar alveolar lavage fluid (BAL) in 
RM cohorts destined for SIV challenge 
Fig. S6. Epitope analysis of RhCMV vaccine-elicited, SIV-specific CD8+ T cell responses in RM 
cohorts destined for SIV challenge 
Fig. S7. Analysis of SIVgag-specific CD4+ and CD8+ T cell response magnitude in tissues of 68-1 vs. 
68-1.2 RhCMV/SIVgag vector vaccinated RMs at necropsy 
Fig. S8. General gating hierarchy for ICS analysis 
Table S1. Epitope analysis summary of all study RMs 
Table S2. Primer/probe sets used for expression analysis of RhCMV encoded inhibitors of 
unconventionally restricted CD8+ T cell priming 
Table S3. RhCMV vector genetic modifications 
Table S4. Raw data file: non-quantitative epitope analysis data 
Table S5. Raw data file: quantitative data 
MTA form (pdf) 
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Figure legends 
Figure 1. RhCMV strain differences. (A) Schematic of the genetic differences between 68-1, 68-1.2, 
and FL (wildtype) RhCMV in the region of the genome encoding the pentameric complex (analogous to 
the ULb’ region of HCMV), showing the inversion-deletion event that occurred during in vitro passage 
of the 68-1 strain and its partial repair in 68-1.2 (with pointed boxes representing distinct exons, the point 
indicating the 3’ end of the ORF). The genomic segments of inversion and deletion indicated by the 
letters A, B and C were adapted from Oxford at al. (11). (B) Representative MHC restriction analysis of 
SIVgag-specific CD8+ T cell responses elicited by strain 68-1 vs. 68-1.2 RhCMV/SIVgag vectors, alone 
and in combination, assessed by ICS analysis of consecutive 15mer peptides with 11 amino acid overlap 
comprising the SIVgag protein sequence. Boxes reflect any above-threshold single 15mer response, 
which were then color-coded based on MHC restriction type analysis (see Methods). In addition, 
responsiveness to the designated MHC-E and MHC-II optimal supertope peptides are indicated by green 
and blue arrowheads, respectively. The figure shows only the SIVgag regions from amino acid 45-75 
and amino acid 100-125 (the regions including the supertopes) of 2 representative RMs, but complete 
epitope analysis results are presented in table S1. These overall data were used to calculate the % of the 
total MHC restriction-assignable SIVgag epitopes that were MHC-Ia-, MHC-E-, and MHC-II-restricted, 
shown at right in red/green/blue, respectively. 
Figure 2. Role of the pentameric complex in RhCMV vector CD8+ T cell response programming. 
(A) Schematic of the genetic configuration of 68-1.2 RhCMV/SIVgag vectors with modified Rh157.5 
and Rh157.4 genes. (B) Representative MHC restriction analysis of SIVgag-specific CD8+ T cell 
responses elicited by the designated Rh157.5 and/or Rh157.4 gene-modified RhCMV vectors, as 
described in Fig. 1 legend. Overall epitope analysis results are shown in table S1. 
Figure 3. Role of myeloid cell tropism in RhCMV vector CD8+ T cell response programming. (A) 
Schematic of the miR-142-3p target sites inserted downstream of both Rh156 and Rh108 (homologs of 
HCMV IE2 and UL79), which are essential for viral replication. Green sequences represent insertion of 
four miR-142-3p recognition sites. Red sequences indicate scrambled nucleotides of the miR-142-3p 
sequence used to create a control vector. Orange boxes represent the Rh108 ORF with a hemagglutinin 
(HA) epitope-tag. (B) Growth analysis of the 68-1.2 control (scrambled sequence) RhCMV vector (left) 
vs. 68-1.2 miR-142-3p RhCMV vector (right) in the presence or absence of miR-142-3p expression. 
Primary rhesus fibroblasts were transfected with negative control or miR-142-3p mimic and infected 24 
hours later with the 68-1.2 miR-142-3p or control RhCMV vectors at an MOI of 0.01. Cell supernatants 
were harvested at the indicated timepoints and titered on primary rhesus fibroblasts. Results are 
representative of 2 independent experiments. (C) Analysis of 68-1.2 miR-142-3p vs control RhCMV 
vector replication in primary macrophages. Macrophages were differentiated in vitro from peripheral 
blood of 3 RMs and infected with 68-1.2 miR-142-3p or scrambled RhCMV at MOI = 5. At the indicated 
times post-infection viral DNA was isolated and total DNA copies were determined using qPCR (mean 
+ SEM of 3 independent experiments shown). (D) Representative MHC restriction analysis of SIVgag-
specific CD8+ T cell responses elicited by 68-1.2 miR-142-3p vs. scrambled RhCMV/SIVgag vectors, 
as described in Fig. 1. Overall epitope analysis results are shown in table S1. 
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Figure 4. Regulation of RhCMV vector CD8+ T cell response programming by non-pentameric 
complex-related genes in the same RhCMV genomic region. (A) Schematic representation of the 
configuration of FL-RhCMV vector in the genetic region of the 68-1 inversion/deletion, compared to 
modified FL-RhCMV vectors in which the gene segments involved in each end of the 68-1 
inversion/deletion (Rh157.5/Rh157.4 and Rh158-162) are separately deleted (single-deleted vectors) or 
both deleted (e.g., double-deleted or dd vector). (B) Representative MHC restriction analysis of SIVgag-
specific CD8+ T cell responses elicited by FL, double-deleted and both single-deleted RhCMV/SIVgag 
vectors, as described in Fig. 1. Overall epitope analysis results are shown in table S1. 
Figure 5. Identification of CMV-encoded inhibitors of unconventionally restricted CD8+ T cell 
response priming. (A,B) Representative MHC restriction analysis of SIV-specific CD8+ T cell 
responses elicited by double-deleted (dd) FL-RhCMV/SIVgag vectors which were engineered to express 
Rh157.5 and Rh157.4 alone, Rh157.5 + Rh157.4, or each of the Rh158-Rh161 alone (see fig. S3A-C for 
genetic configurations), as described in Fig. 1. (C) Representative MHC restriction analysis of SIV-
specific CD8+ T cell responses elicited by double-deleted FL-RhCMV/SIVgag vectors which are 
engineered to individually express UL128, UL130, UL146 and UL147, the HCMV orthologs of the 
Rh157.5-Rh157.4 and Rh158-Rh161 genes (see fig. S3D for genetic configurations). Note that MHC 
restriction analysis of the parent dd FL-RhCMV/SIVgag vector-elicited CD8+ T cell response is shown 
in Fig. 4B (bottom panel). For A-C, overall epitope analysis results are shown in table S1.  
Figure 6. Immunogenicity of differentially CD8+ T cell response-programmed RhCMV vectors. 
(A) Protocol for the comparison of the immunogenicity and efficacy of 68-1, 68-1.2, and DRh157.5 68-
1.2 RhCMV/SIV vector sets (each set comprised of 3 vectors individually expressing SIV Gag, 
Rev/Tat/Nef, and 5’-Pol inserts), and the combination of 68-1 and 68-1.2 vector sets (n = 15 RMs per 
group). (B,C) Longitudinal and plateau-phase analysis of the vaccine-elicited SIV Gag-, Rev/Tat/Nef-, 
and 5’-Pol-specific CD4+ and CD8+ T cell responses in peripheral blood of the RMs vaccinated with the 
designated vector sets. In B, the background-subtracted frequencies of cells producing TNF and/or IFN-
g by flow cytometric ICS assay to peptide mixes comprising each of the SIV inserts within the memory 
CD4+ or CD8+ T cell subsets were summed for overall responses with the figure showing the mean (+ 
SEM) of these overall responses at each time point (area-under-the-curve was used to quantitatively 
compare longitudinal response profiles). In C, boxplots compare the total and individual SIV insert-
specific CD4+ and CD8+ T cell response frequencies between the vaccine groups during the vaccine 
phase plateau (each data point is the mean of response frequencies in all samples from weeks 61-90 post-
first vaccination). (D) Longitudinal analysis of the vaccine-elicited CD8+ T cell responses to MHC-E-
restricted [Gag276-284 (69) and Gag482-490 (120)] and MHC-II-restricted [Gag211-222 (53) and Gag290-301 (73)] 
SIVgag supertopes in peripheral blood of each vaccine group by ICS assay. Wilcoxon p-values for 
comparison of all response parameters shown in panels B-D for the 68-1-only vaccine to all other 
vaccines (which are individually designated by the color code shown in panel A) are shown where 
significant (adjusted for multiple comparisons in panels C and D).  
Figure 7. Differentiation of CD8+ T cells elicited by differentially response-programmed RhCMV 
vectors. (A) Boxplots compare the memory differentiation phenotype of the vaccine-elicited CD4+ and 
CD8+ memory T cells in peripheral blood of the same RM cohorts reported in Fig. 6 responding to 
overall SIV Gag 15mer peptide mix with TNF and/or IFN-g production during the vaccine phase plateau 
(24-85 weeks post-first vaccination). Memory differentiation state was based on CD28 and CCR7 
expression, delineating central memory (TCM), transitional effector-memory (TTrEM), and effector-
memory (TEM), as designated. (B) Boxplots compare the frequency of vaccine-elicited CD4+ and CD8+ 
memory T cells in peripheral blood responding to the overall SIV Gag 15mer peptide mix with TNF, 
IFN-g, IL-2, and MIP-1b production, alone and in all combinations, in the same samples as panel A. 
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Wilcoxon p-values for comparison of all response parameters shown in panels A and B for the 68-1-only 
vaccine to all other vaccines are shown where significant (adjusted for multiple comparisons).  
Figure 8. Efficacy of differentially programmed RhCMV vectors. (A-E) Assessment of the outcome 
of SIV infection after repeated, limiting dose SIVmac239 challenge (see Fig. 6A) of the designated vaccine 
groups by longitudinal analysis of plasma viral load (left panels) and de novo development of SIVvif-
specific CD4+ (middle panels) and CD8+ (right panels) T cell responses. RMs were challenged until the 
onset of any sustained above-threshold SIVvif-specific T cell response, with the SIV dose administered 
2 or 3 weeks prior to the initial response detection considered the infecting challenge (week 0). The n in 
each panel reflects the total number of RMs with such documented take of SIV infection during the 
challenge period. RMs with sustained viremia were considered non-protected (black); RMs with no or 
transient viremia but demonstrating sustained above-threshold SIVvif-specific T cell responses were 
considered protected (red) (6-8). Binomial exact p-values are shown where the proportion of protected 
RMs in a vaccine group differs significantly from the unvaccinated group. (F) Bone marrow (BM), 
peripheral lymph node (LN) and peripheral blood mononuclear cell (PBMC) samples from all vaccine-
protected RMs (red) and 2 non-protected RMs (black) for comparison (left panel), collected from 
between day 28 and 56 post-SIV infection, were analyzed by nested, quantitative PCR/RT-PCR for cell-
associated SIV DNA and RNA. The dotted line indicates the threshold of detection (B.T. = below 
threshold) with data points below this line reflecting no positive reactions across all replicates.  
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Figure S1. Functional pentameric complex analysis of 68-1.2-based RhCMV vectors. The indicated 
vectors were used to infect triplicate repeat cultures of primary rhesus fibroblasts (RF) or rhesus retinal 
pigment epithelial cells (RPE) at multiplicities of infection of 0.3 and 10, respectively (predetermined to 
give infection levels of 20-30 percent after 48 hours). All samples were harvested at 48 hours post 
infection and subsequently fixed and permeabilized before infection rates (% infected cells) were 
determined by flow cytometry using a RhCMV-specific antibody. Mean infection rates in RFs were set 
to 100% and infection rates in RPEs are shown in relation to RFs (+ SEM). Reduced infectivity of RPEs 
relative to RFs indicates abrogation of pentameric complex function. RhCMV strains 68-1 and 68-1.2 


















































































Figure S2. Protein sequence comparison of RhCMV/HCMV orthologs RhCMV157.5/UL128, 
Rh157.4/ UL130 and Rh158-161/UL146-147.  Shown are complete protein sequence alignments of the 
HCMV/RhCMV encoded UL146 family members in comparison to human CXCL-1 (#NP_001502) (A), 
the UL128/Rh157.5 proteins in comparison to human CCL-5 (#NG_015990) (B) and the UL130/ 
Rh157.4 proteins in comparison to human CXCL-8 (#NG_029889) (C). The conserved structural 
cysteines important for chemokine function are highlighted in blue while all other conserved amino acids 
are highlighted in grey. Also highlighted in panel C (magenta) are two of the four cysteines characteristic 
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Figure S3. Genetic configuration of gene-modified double-deleted (dd) RhCMV FL vectors. (A-D) 
Schematic representation of the RhCMV genome modifications of the dd RhCMV/SIVgag FL (dd-FL) 
vectors used to determine the ability of the designated RhCMV and HCMV genes to influence the MHC-
restriction of vector elicited CD8+ T cell response. Panel A shows the RhCMV genome region encoding 
the pentameric complex subunits and UL146-family chemokine homologs (analogous to the ULb’ region 
of HCMV) of the parent dd RhCMV FL vector, with panels B-D showing the same genome region of 
dd RhCMV FL vectors engineered to express the designated genes from the Rh161 locus. Each box 
represents a distinct exon and each dashed box highlighted in red represents a deleted region (Δ) of the 
corresponding genes highlighted in red in RhCMV FL (see Fig. 1A). Panels B, C, and D correspond to 
the CD8+ T cell response restriction data shown in Figs. 5A, 5B and 5C, respectively. 
 
 
































































































Figure S4. Transcriptional analysis of Rh158-Rh161 region genes in RhCMV FL in comparison to 
RhCMV 68-1 and 68-1.2. Total RNA was isolated from RM fibroblasts infected with a MOI = 5 of 
RhCMV-FL, RhCMV 68-1, or RhCMV 68-1.2 at 0, 4, 8, 12, 24, 36, and 48 hours post infection (hpi). 
Uninfected rhesus fibroblasts were used as a negative control. The mRNA copy number of each gene 
relative to the housekeeping gene GAPDH was determined by quantitative reverse transcriptase PCR 
(qRT-PCR) analysis at the indicated time points. As a positive control, the transcripts of Rh156, Rh189, 
and Rh137 (upper panels) representing immediate early (IE), early (E), and late (L) genes, respectively, 
were included (primer-probe pairs shown in table S2). The lack of expression of the pentameric complex 
genes Rh157.5 and Rh157.4 but not Rh157.6 was confirmed in RhCMV 68-1 infected cells whereas all 
three genes were co-expressed in 68-1.2 and RhCMV FL. Compared to RhCMV FL, quantification of 
the six Rh158-Rh161 region transcripts (lower two panels) confirmed the lack of Rh158.2, Rh158.3, and 
Rh161.1 gene expression in 68-1 and 68-1.2-infected cells and revealed substantially lower expression 
levels of Rh158, Rh158.1, and Rh161 genes at late times of infection. 
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Figure S5. Analysis of SIV-specific T cell responses in bronchoalveolar alveolar lavage fluid (BAL) 
in RM cohorts destined for SIV challenge. (A) Longitudinal analysis of the total vaccine-elicited SIV 
-specific CD4+ and CD8+ T cell responses (sum of Gag, Rev/Tat/Nef, and 5’-Pol-specifc responses) in 
BAL of the RM vaccinated with 68-1, 68-1.2, and 68-1.2 DRh157.5 vector sets and the combination of 
the 68-1 and 68-1.2 vector sets (n=15 for each cohort). Responses to whole SIV protein peptide mixes 
were assessed by a flow cytometric ICS assay (based on induction of TNF and/or IFN-g), as described 
in Fig. 6 (gating hierarchy shown in fig. S8). (B) Plateau phase analysis of the same ICS data showing 
total SIV-specific responses and responses to each individual SIV insert. Each data point is the mean of 
response frequencies in all samples from 61-88 weeks post-first vaccination. Wilcoxon p-values for 
comparison of the 68-1-only vaccine to the other vaccines are shown where significant (unadjusted for 
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Figure S6. Epitope analysis of RhCMV vaccine-elicited, SIV-specific CD8+ T cell responses in RM 
cohorts destined for SIV challenge. The epitope targeting characteristics of the CD8+ T cell responses 
elicited by each vector set (RhCMV/SIVgag, RhCMV/SIVretanef, and RhCMV/SIV5’pol) in the RM 
cohorts destined for SIV challenge were analyzed for indicated portions of each insert (SIVgag177-311, 
SIVrev1-107, SIVpol257-375 for the SIVgag, SIVretanef, and SIV5’-pol inserts, respectively, corresponding 
to 15mers 45-75, 1-24, and 65-91). Grey boxes reflect insufficient cell availability to complete restriction 
analysis. Blue and green dots indicate independently confirmed MHC-II- and MHC-E-restricted SIVgag 
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Figure S7. Analysis of SIVgag-specific CD4+ and CD8+ T cell response magnitude in tissues of 68-
1 vs. 68-1.2 RhCMV/SIVgag vector vaccinated RM at necropsy. Mononuclear cells from blood and 
the indicated tissues from RM inoculated with either the 68-1 (blue) or 68-1.2 (green) RhCMV/SIVgag 
vectors were obtained at necropsy for analysis of SIV Gag-specific CD4+ and CD8+ T cell responses. 
Responses to whole SIV Gag protein peptide mix were assessed by a flow cytometric ICS assay (based 
on induction of TNF and/or IFN-g) as described in Fig. 6 (gating hierarchy shown in fig. S8). Results 
for peripheral and mesenteric LNs reflect the average of responses from 3 or 4 different LNs of each 
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Figure S8. General gating hierarchy for ICS analysis. The figure illustrates the general gating steps 
used to obtain response frequencies based on induction of TNF and/or IFN-g after antigenic stimulation 
(a total SIVgag response in this example). Initial gates (top row) successively restrict analysis to CD3+ 
T cells, small lymphocytes and then separately the CD4+ and CD8+ T cell subsets, while providing quality 
control (checking collection dynamics via time parameter). The next step (middle row) defines the Ag 
responding subset by determining the response clusters defined by upregulation of CD69 and, separately, 
induction of TNF and IFN-g, using Boolean gating to define the % of cells with both upregulated CD69 
and expression of TNF and IFN-g, alone or together (bottom row). Identical gating is performed on 
negative control cultures to define background. After subtracting background, the % of cells in this gate 
defines the response frequencies for all routine response assays (Figs. 1-6, with frequencies > 0.05% 
above background reflecting a positive response). For memory subset phenotyping (Fig. 7A), this 
CD69+, TNF- and/or IFN-g-expressing population is gated to determine the fraction of this population 
expressing the memory markers CD28 vs. CCR7, defining central memory (TCM), transitional effector-
memory (TTrEM), and effector-memory (TEM), as designated (bottom row). The approach to polycytokine 
analysis (Fig. 7B) is similar except that the cytokine response definition also includes IL-2 and MIP-1b 
expression, with Boolean gating used to ascertain the fraction of the overall responding subset (CD69+ 
plus any cytokine) that expresses each of these cytokines alone or in all combinations.  




















































































































































































Table S1. Epitope analysis summary of all study RM. The table shows the total numbers of SIV Gag 
15mer peptide-specific CD8+ T cell responses that were restriction-assignable for each of the designated 
RhCMV/SIVgag vectors, the corresponding estimated number of independent epitopes, and the 


















68-1 15 1047 704 0 (0) 320 (45.5) 384 (54.5)
68-1.2 14 613 418 418 (100) 0 (0) 0 (0)
*RhCMV FL ¨Rh157.5/Rh157.4 + ¨Rh158-Rh161
68-1.2 Rh157.5 (STOP) Rh157.4 (STOP) 2 115 78 0 (0) 39 (50.0) 39 (50.0)
68-1.2 ¨Rh157.5 15 391 267 104 (39.0) 0 (0) 163 (61.0)
68-1.2 ¨Rh157.4 4 219 157 72 (45.9) 0 (0) 85 (54.1)
68-1.2 CC1 + CC2 mut-Rh157.5 2 105 70 34 (48.6) 0 (0) 36 (51.4)
68-1.2 miR-142-3p-restricted 3 143 95 11 (11.6) 0 (0) 84 (88.4)
68-1.2 miR-control (142-3p scrambled) 2 103 73 73 (100) 0 (0) 0 (0)
68-1 + 68-1.2 14 940 641 136 (21.2) 220 (34.3) 285 (44.5)
RhCMV FL 2 120 76 76 (100) 0 (0) 0 (0)
FL ¨Rh157.5/Rh157.4 3 167 108 108 (100) 0 (0) 0 (0)
FL ¨Rh158-Rh161 2 98 68 68 (100) 0 (0) 0 (0)
dd FL* 3 192 124 0 (0) 60 (48.4) 64 (51.6)
dd FL + Rh157.5 1 55 37 17 (45.9) 0 (0) 20 (54.1)
dd FL + Rh157.4 1 61 40 23 (57.5) 0 (0) 17 (42.5)
dd FL + Rh157.5/Rh157.4 2 111 70 70 (100) 0 (0) 0 (0)
dd FL + Rh158 1 53 34 34 (100) 0 (0) 0 (0)
dd FL + Rh158.1 1 49 35 35 (100) 0 (0) 0 (0)
dd FL + Rh158.2 1 55 35 35 (100) 0 (0) 0 (0)
dd FL + Rh158.3 1 53 35 35 (100) 0 (0) 0 (0)
dd FL + Rh161.1 1 55 37 37 (100) 0 (0) 0 (0)
dd FL + Rh161 1 62 41 41 (100) 0 (0) 0 (0)
dd FL + HCMV UL128 2 101 74 35 (47.3) 0 (0) 39 (52.7)
dd FL + HCMV UL130 2 99 73 34 (46.6) 0 (0) 39 (53.4)
dd FL + HCMV UL146 2 98 72 72 (100) 0 (0) 0 (0)
dd FL + HCMV UL147 2 114 78 78 (100) 0 (0) 0 (0)
dd FL + HCMV UL146 STOP 2 112 79 0 (0) 38 (48.1) 41 (51.9)
Table S1. Epitope analysis summary of all study RM. The table shows the total numbers of SIVgag 15mer peptide-specific CD8+ T cell 
responses that were restriction-ass gnable for e ch of the designated RhCMV/SIVgag vector , the corresponding number of independent 
epitopes, and the restriction type of each of the independent epitope-specific responses (see Methods).
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Rh156 (IE1) 
Forward 5’ AGTATGCCAAGCCTCATATTAAGGA 3’ 
Reverse 5’ GCATATGGTGCTTGCTCTTAGAAG 3’ 
Probe 6FAMAAGGTGCTGGACCCMGBNFQ 
Rh189 (E) 
Forward 5’ GGAGCGCCCGGTAAGG 3’ 
Reverse 5’ CGATGGAGTTTTATGCTTTGCA 3’ 
Probe 6FAMTCCAGTGCATCTGAATCMGBNFQ 
Rh137 (L) 
Forward 5’ GGCGCAACATACTACCCAGAA 3’ 
Reverse 5’ GTAGCCATCCCCATCTTCCA 3’ 
Probe 6FAMCACAACTAACTCTGGCCTTMGBNFQ 
Rh157.5 
Forward 5’ CTCAACTACCTCAGGTCAATGTGACT 3’ 
Reverse 5’ CAGGCGTTGGTGGCATAGTA 3’ 
Probe 6FAMTGCTACCTCTGCTTCATMGBNFQ 
Rh157.4 
Forward 5’ GCGAACGGCGAGATCAAC 3’ 
Reverse 5’ TGGCTTCGGTGCCACTTG 3’ 
Probe 6FAMAACGCCAAGGTCAGCTMGBNFQ 
Rh157.6 
Forward 5’ AAAACACAAAACAACCCCATCTTAC 3’ 
Reverse 5’ AATGTGATGAGTTTCTTTGCTGAAA 3’ 
Probe 6FAMCGTAGGATTGGATTAATTMGBNFQ 
Rh158 
Forward 5’ TCTACAACCACTACCCCCTAACG 3’ 
Reverse 5’ TTTGGGAGCACAGCAATCAC 3’ 
Probe 6FAMAAATTGCACCAAACAAGAMGBNFQ 
Rh158.1 
Forward 5’ CGTAACCCGTCGGTGTTTG 3’ 
Reverse 5’ GCTGCGGCTTCAAACTTATGTG 3’ 
Probe 6FAMATTGGATAAGCAAACATGMGBNFQ 
Rh158.2 
Forward 5’ ATAATCTCGGTTTTGTGACATTCACT 3’ 
Reverse 5’ GCGTACCATGAAAGGCGTTAA 3’ 
Probe 6FAMTTTCACTATCTGAATATCTGMGBNFQ 
Rh158.3 
Forward 5’ CCCAAAACGATGGGTACGTT 3’ 
Reverse 5’ GCCGATGATGAAGAAAATGTTG 3’  
Probe 6FAMCTCCGGGAATTTTMGBNFQ 
Rh161.1 
Forward 5’ TCGGTTACTTCGCACCTAGGA 3’ 
Reverse 5’ AGAATTCCACACAGGACACTATGC 3’ 
Probe 6FAMCCGCATATTCAATTGATMGBNFQ 
Rh161 
Forward 5’ AAAATCAGACTGTCTCTGGCTTCA 3’ 
Reverse 5’ GGAAATGTGCTATTGCCTCGTTA 3’ 
Probe 6FAMAGTACGGCTCACCCTGTMGBNFQ 
GAPDH 
Forward 5’ TTCAACAGCGACACCCACTCT 3’ 
Reverse 5’ GTGGTCGTTGAGGGCAATG 3’ 
Probe 6FAMCCACCTTCGACGCTGGMGBNFQ 
Table S2. Primer/probe sets used for expression analysis of RhCMV encoded inhibitors of 
unconventionally restricted CD8+ T cell priming. These primers and probes were used for the qRT-
PCR analysis shown in fig. S4. 
 
 
 
 
 
 
 
